Drug Profile
Supra seasonal universal influenza vaccine inactivated - GlaxoSmithKline
Alternative Names: GSK3816302A; SUIVsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention, In volunteers) in Belgium (IM)
- 28 Oct 2020 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention, In volunteers) in USA (IM)
- 23 Jun 2020 GlaxoSmithKline completes a phase I trial in Influenza virus infections (In volunteers, Prevention) in the US and Belgium (NCT03275389) (EudraCT2017-001584-20)